Covaxin had much lower adverse effects and overall favourable short-term safety profile in adolescents: Study

Thursday, 16 May 2024
Bharat Biotech’s indigenously developed Covid-19 vaccine Covaxin was overall found to have “much lower” AEFI (adverse effects following immunisation) rates in adolescents with a favourable short-term safety profile as compared to those reported with mRNA vaccines but adolescent females and those with a history of allergy were at a 1.6 times and three times increased risk of AEFI after taking Covaxin.

👓 View full article

0 shares	Share Tweet Save Post Send

💡 newsR Knowledge: Other News Mentions

COVID-19 Contagious disease caused by SARS-CoV-2

'Arguably we shouldn't have gone' - Root on 2021-22 Ashes

Former captain Joe Root says England "arguably" should not have gone on the last Ashes tour of Australia, amid Covid restrictions.
BBC Sport 3 days ago

Covaxin had much lower adverse effects and overall favourable short-term safety profile in adolescents: Study

💡 newsR Knowledge: Other News Mentions

COVID-19 Contagious disease caused by SARS-CoV-2

'Arguably we shouldn't have gone' - Root on 2021-22 Ashes

You Might Like